When Johnson & Johnson's venture arm and British growth investor BGF decided to lead a $14 million extension to TRIMTECH Therapeutics' seed round in June 2026, they weren't just buying into another protein degradation story. They were placing a bet on fifteen years of painstaking research into a molecular mechanism most drug developers had written off as too finicky to harness.
The extension, announced June 23, brings Cambridge-based TRIMTECH's total seed haul to $47 million—a figure that stands among the heftier early-stage raises in European biotech this year. Both JJDC and BGF secured board seats in the neuroscience-focused company, joining what has become a conspicuously crowded cap table.
That initial round of $33 million, announced March 5, 2025, and co-led by Cambridge Innovation Capital and the Dementia Discovery Fund (part of SV Health Investors), already featured a who's-who of pharmaceutical corporate venturing: M Ventures, Pfizer, Eli Lilly. Add in specialist early-stage shops like MP Healthcare Venture Management, Cambridge Enterprise Ventures, and Start Codon, and you have the makings of a syndicate that suggests either high conviction or hedge-your-bets caution. Perhaps both.
The TRIM21 Gambit
TRIMTECH spun out of the MRC Laboratory of Molecular Biology and the UK Dementia Research Institute at Cambridge in 2023, carrying with it years of academic spadework on an E3 ligase called TRIM21. The promise? Selectively destroying the toxic, misfolded protein clumps implicated in Alzheimer's, Parkinson's, and Huntington's—while leaving the properly folded, functional versions untouched.
It's a selectivity problem that has bedeviled the field. Go after amyloid plaques too aggressively and you risk disrupting normal protein function. TRIMTECH's scientific founders—Dr. Leo James, a fellow of the Royal Society at MRC-LMB, and Dr. Will McEwan at the UK DRI—published early proof of concept in PNAS back in 2017, showing TRIM21 could inhibit seeded tau aggregation. More recent work in Science and Cell during 2024 fleshed out the company's two core approaches: TRIMTAC heterobifunctional degraders and TRIMGLUE molecular glues, both designed as CNS-penetrant small molecules.
Dr. Damian Crowther, who came through as an entrepreneur-in-residence at both CIC and DDF before becoming TRIMTECH's head of research, rounds out the founding scientific trio. James and McEwan now serve as chief scientific advisers.
The CEO chair belongs to Dr. Nicki Thompson, a repeat founder who previously built and led Amphista Therapeutics, another Cambridge outfit working the targeted degradation space, and held business development roles at Roche and GSK before that. Her chemistry bench is staffed by veterans: Dr. Alex Alanine, formerly of Roche and Nanna Therapeutics, leads the group as SVP; Dr. Andrea Testa, an Amphista co-founder with deep roots in the Ciulli lab, is VP of chemistry.
Board Seats and Strategic Bets
With the latest extension, Nadiya Ishnazarova from JJDC and Lucy Edwardes-Jones from BGF have taken non-executive director slots alongside existing board representatives from CIC, DDF, Pfizer Ventures, and M Ventures. Alison Lawton, named independent chair in December 2025, presides over what is now a notably pharmaceutical-heavy governance structure.
The company's stated plan for the $47 million is to "progress its proprietary platforms and differentiated portfolio," though TRIMTECH has stopped short of disclosing preclinical milestones or timelines to an investigational new drug filing. As of mid-June, the company's LinkedIn profile listed 21 associated profiles, though the official company size bracket is given as 2-10 employees, and no official headcount has been confirmed.
A Crowded Field Gets Crowdier
TRIMTECH is hardly alone in chasing aggregate-selective degradation. Biogen inked a multi-target collaboration with Neomorph in October 2024 that lists Alzheimer's among its disease targets. Convergen Life Sciences, another TRIM21-focused startup, pulled in $10 million in seed financing around late 2025 or early this year. And Enodia Therapeutics closed a €20.7 million seed round in January, co-led by Pfizer Ventures, for its own targeted protein degradation platform.
That makes for a competitive landscape, one in which subtle mechanistic differences and execution speed will matter as much as the science itself. TRIMTECH has assembled a scientific advisory board weighted with credibility—Prof. Alessio Ciulli chairs it, joined by Dr. Adam Gilbert and Dr. Mike Hutton, Eli Lilly's former chief scientific officer for neurodegeneration. The company plans to present at the Gordon Research Conference on Induced Proximity Modalities & Therapeutics in June and the Alzheimer's Association International Conference in London this July.
Whether TRIMTECH's aggregate-selective twist proves meaningfully differentiated—or merely incrementally better—remains the open question. What's clear is that the company has secured enough capital, and enough big-name partnerships, to get a thorough crack at answering it. In an era when Alzheimer's drug development has burned through billions with precious little to show for it, that may be all any startup in this space can realistically ask for.
